Paschalis Karakasis, Antonios P Antoniadis, Panagiotis Theofilis, Panayotis K Vlachakis, Nikias Milaras, Dimitrios Patoulias, Theodoros Karamitsos, Nikolaos Fragakis
{"title":"房颤的数字孪生模型:描绘精准治疗的未来?","authors":"Paschalis Karakasis, Antonios P Antoniadis, Panagiotis Theofilis, Panayotis K Vlachakis, Nikias Milaras, Dimitrios Patoulias, Theodoros Karamitsos, Nikolaos Fragakis","doi":"10.3390/jpm15060256","DOIUrl":null,"url":null,"abstract":"<p><p>Atrial fibrillation (AF) is the most common sustained arrhythmia and a major contributor to stroke and cardiovascular morbidity. However, current approaches to rhythm control and stroke prevention are often limited by variable treatment responses and population-based risk stratification tools that fail to capture individual disease mechanisms. Digital twin technology-computational models built using patient-specific anatomical and physiological data-has emerged as a promising approach to address these limitations. In the context of AF, left atrial (LA) digital twins integrate structural, electrophysiological, and hemodynamic information to simulate arrhythmia behavior, therapeutic response, and thromboembolic risk with high mechanistic fidelity. Recent applications include stroke risk prediction using computational fluid dynamics, in silico testing of antiarrhythmic drugs, and virtual planning of catheter ablation strategies. These models have shown potential to enhance the personalization of care, offering a more nuanced and predictive framework than conventional scoring systems or imaging alone. Despite promising progress, challenges related to model personalization, computational scalability, and clinical validation remain. Nevertheless, LA digital twins are poised to advance the precision management of AF by bridging in silico modeling with real-world decision-making. This review summarizes the current state and future directions of left atrial digital twin models in AF, focusing on their application in stroke risk prediction, pharmacologic decision-making, and ablation strategy optimization.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194066/pdf/","citationCount":"0","resultStr":"{\"title\":\"Digital Twin Models in Atrial Fibrillation: Charting the Future of Precision Therapy?\",\"authors\":\"Paschalis Karakasis, Antonios P Antoniadis, Panagiotis Theofilis, Panayotis K Vlachakis, Nikias Milaras, Dimitrios Patoulias, Theodoros Karamitsos, Nikolaos Fragakis\",\"doi\":\"10.3390/jpm15060256\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Atrial fibrillation (AF) is the most common sustained arrhythmia and a major contributor to stroke and cardiovascular morbidity. However, current approaches to rhythm control and stroke prevention are often limited by variable treatment responses and population-based risk stratification tools that fail to capture individual disease mechanisms. Digital twin technology-computational models built using patient-specific anatomical and physiological data-has emerged as a promising approach to address these limitations. In the context of AF, left atrial (LA) digital twins integrate structural, electrophysiological, and hemodynamic information to simulate arrhythmia behavior, therapeutic response, and thromboembolic risk with high mechanistic fidelity. Recent applications include stroke risk prediction using computational fluid dynamics, in silico testing of antiarrhythmic drugs, and virtual planning of catheter ablation strategies. These models have shown potential to enhance the personalization of care, offering a more nuanced and predictive framework than conventional scoring systems or imaging alone. Despite promising progress, challenges related to model personalization, computational scalability, and clinical validation remain. Nevertheless, LA digital twins are poised to advance the precision management of AF by bridging in silico modeling with real-world decision-making. This review summarizes the current state and future directions of left atrial digital twin models in AF, focusing on their application in stroke risk prediction, pharmacologic decision-making, and ablation strategy optimization.</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194066/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15060256\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15060256","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Digital Twin Models in Atrial Fibrillation: Charting the Future of Precision Therapy?
Atrial fibrillation (AF) is the most common sustained arrhythmia and a major contributor to stroke and cardiovascular morbidity. However, current approaches to rhythm control and stroke prevention are often limited by variable treatment responses and population-based risk stratification tools that fail to capture individual disease mechanisms. Digital twin technology-computational models built using patient-specific anatomical and physiological data-has emerged as a promising approach to address these limitations. In the context of AF, left atrial (LA) digital twins integrate structural, electrophysiological, and hemodynamic information to simulate arrhythmia behavior, therapeutic response, and thromboembolic risk with high mechanistic fidelity. Recent applications include stroke risk prediction using computational fluid dynamics, in silico testing of antiarrhythmic drugs, and virtual planning of catheter ablation strategies. These models have shown potential to enhance the personalization of care, offering a more nuanced and predictive framework than conventional scoring systems or imaging alone. Despite promising progress, challenges related to model personalization, computational scalability, and clinical validation remain. Nevertheless, LA digital twins are poised to advance the precision management of AF by bridging in silico modeling with real-world decision-making. This review summarizes the current state and future directions of left atrial digital twin models in AF, focusing on their application in stroke risk prediction, pharmacologic decision-making, and ablation strategy optimization.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.